FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2481103619> ?p ?o ?g. }

• W2481103619 abstract "BACKGROUND: The proteosome is clinically validated as a target for cancer therapeutics. Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1/2 studies of CFZ reported signals of clinical activity in solid tumors. The aim of this study was to investigate the activity of CFZ in triple negative breast cancer models. METHODS: A diverse panel of human triple negative breast cancer cell lines was used to investigate the anti-tumor activity of CFZ. Cell viability following CFZ treatment was assessed using MTT assay. Proliferation was monitored both with IncuCyte Zoom real-time imaging system and 3D-ON-TOP clonogenic assay. Annexin-V flow cytometry was used to measure apoptosis. Apoptotic protein levels were measured with Western blot and proteome profiler array. MCL1 and Ki67 expression were also assessed using immunocytochemistry. RESULTS: CFZ had marked anti-proliferative activity in MDA-MD231, MDA-MB468, BT20, and SUM149 TNBC cell lines, with IC50 values following 96-hour exposure from 8 nM to 25 nM by MTT assay. The anti-proliferative activity of CFZ was observed by 3D-ON-TOP clonogenic assay. The anti-proliferative activity of CFZ was also demonstrated with IncuCyte proliferation assay. Proliferation was inhibited by low nanomolar concentrations in both MDA-MB468 and BT20 cells. Western blot analysis of CFZ-treated BT20, MDA-MB231 and MDA-MB468 cells showed cleavage of poly ADP ribose polymerase (PARP) and CASPASE-3, indicative of apoptosis, and induction of microtubule-associated protein-1 light chain-3B (LC3B), indicative of autophagy. However, expression level of anti-apoptotic protein MCL1 was increased in RAS-RAF mutated cells (MDA-MB231) but not in PTEN-null MDA-MD468 cells following the treatment of CFZ. Double immune-fluorescence staining of MDA-MB231 cells following the treatment of CFZ showed higher expression of MCL1 but no change in Ki67 expression. Interestingly, a combination of CFZ and TOR kinase inhibitor (MLN0128) enhanced cleaved CASPASE3 and BIM expression with a concomitant increased induction of apoptosis (annexinV expression) in MDA-MB231 cells. CONCLUSIONS: CFZ demonstrated anti-proliferative activity in TNBC cell lines in vitro. Flow cytometric analysis of annexin V-positive cells and Western blot expression of cleaved CASPASE 3, cleaved PARP and BIM indicated that CRZ -induced TNBC cell death through an apoptosis-dependent manner. Citation Format: Mathew Larson, Jennifer H. Carlson, Yuliang Sun, Tonia Bucholz, Casey Williams, Nandini Dey, Brian Leyland-Jones, Pradip De. Carfilzomib demonstrates antiproliferative and proapoptotic activities in preclinical triple-negative breast cancer models. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3506." @default.
• W2481103619 created "2016-08-23" @default.
• W2481103619 creator A5012509754 @default.
• W2481103619 creator A5030281378 @default.
• W2481103619 creator A5032831608 @default.
• W2481103619 creator A5042403689 @default.
• W2481103619 creator A5065634508 @default.
• W2481103619 creator A5068271757 @default.
• W2481103619 creator A5073999355 @default.
• W2481103619 creator A5090896997 @default.
• W2481103619 date "2016-07-15" @default.
• W2481103619 modified "2023-09-25" @default.
• W2481103619 title "Abstract 3506: Carfilzomib demonstrates antiproliferative and proapoptotic activities in preclinical triple-negative breast cancer models" @default.
• W2481103619 doi "https://doi.org/10.1158/1538-7445.am2016-3506" @default.
• W2481103619 hasPublicationYear "2016" @default.
• W2481103619 type Work @default.
• W2481103619 sameAs 2481103619 @default.
• W2481103619 citedByCount "0" @default.
• W2481103619 crossrefType "proceedings-article" @default.
• W2481103619 hasAuthorship W2481103619A5012509754 @default.
• W2481103619 hasAuthorship W2481103619A5030281378 @default.
• W2481103619 hasAuthorship W2481103619A5032831608 @default.
• W2481103619 hasAuthorship W2481103619A5042403689 @default.
• W2481103619 hasAuthorship W2481103619A5065634508 @default.
• W2481103619 hasAuthorship W2481103619A5068271757 @default.
• W2481103619 hasAuthorship W2481103619A5073999355 @default.
• W2481103619 hasAuthorship W2481103619A5090896997 @default.
• W2481103619 hasConcept C117262875 @default.
• W2481103619 hasConcept C121608353 @default.
• W2481103619 hasConcept C126322002 @default.
• W2481103619 hasConcept C153911025 @default.
• W2481103619 hasConcept C190283241 @default.
• W2481103619 hasConcept C2778367456 @default.
• W2481103619 hasConcept C2780108899 @default.
• W2481103619 hasConcept C2780110267 @default.
• W2481103619 hasConcept C2780783641 @default.
• W2481103619 hasConcept C502942594 @default.
• W2481103619 hasConcept C530470458 @default.
• W2481103619 hasConcept C53227056 @default.
• W2481103619 hasConcept C55493867 @default.
• W2481103619 hasConcept C71924100 @default.
• W2481103619 hasConcept C86803240 @default.
• W2481103619 hasConceptScore W2481103619C117262875 @default.
• W2481103619 hasConceptScore W2481103619C121608353 @default.
• W2481103619 hasConceptScore W2481103619C126322002 @default.
• W2481103619 hasConceptScore W2481103619C153911025 @default.
• W2481103619 hasConceptScore W2481103619C190283241 @default.
• W2481103619 hasConceptScore W2481103619C2778367456 @default.
• W2481103619 hasConceptScore W2481103619C2780108899 @default.
• W2481103619 hasConceptScore W2481103619C2780110267 @default.
• W2481103619 hasConceptScore W2481103619C2780783641 @default.
• W2481103619 hasConceptScore W2481103619C502942594 @default.
• W2481103619 hasConceptScore W2481103619C530470458 @default.
• W2481103619 hasConceptScore W2481103619C53227056 @default.
• W2481103619 hasConceptScore W2481103619C55493867 @default.
• W2481103619 hasConceptScore W2481103619C71924100 @default.
• W2481103619 hasConceptScore W2481103619C86803240 @default.
• W2481103619 hasLocation W24811036191 @default.
• W2481103619 hasOpenAccess W2481103619 @default.
• W2481103619 hasPrimaryLocation W24811036191 @default.
• W2481103619 hasRelatedWork W1041613361 @default.
• W2481103619 hasRelatedWork W1965483363 @default.
• W2481103619 hasRelatedWork W2041903098 @default.
• W2481103619 hasRelatedWork W2394850978 @default.
• W2481103619 hasRelatedWork W2472048047 @default.
• W2481103619 hasRelatedWork W2477201797 @default.
• W2481103619 hasRelatedWork W2506900839 @default.
• W2481103619 hasRelatedWork W2520959410 @default.
• W2481103619 hasRelatedWork W2560848513 @default.
• W2481103619 hasRelatedWork W2576848049 @default.
• W2481103619 hasRelatedWork W2727091524 @default.
• W2481103619 hasRelatedWork W2895872706 @default.
• W2481103619 hasRelatedWork W2936048640 @default.
• W2481103619 hasRelatedWork W3043528227 @default.
• W2481103619 hasRelatedWork W3045165385 @default.
• W2481103619 hasRelatedWork W3110434647 @default.
• W2481103619 hasRelatedWork W3115208379 @default.
• W2481103619 hasRelatedWork W3129346088 @default.
• W2481103619 hasRelatedWork W3139394554 @default.
• W2481103619 hasRelatedWork W2783670133 @default.
• W2481103619 isParatext "false" @default.
• W2481103619 isRetracted "false" @default.
• W2481103619 magId "2481103619" @default.
• W2481103619 workType "article" @default.